Indraprastha Medical Corporation Ltd vs Nidan Laboratories Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Indraprastha Medical Corporation Ltd is ₹ 305.15 as of 30 Oct 15:30 . The P/E Ratio of Indraprastha Medical Corporation Ltd changed from 215 on March 2021 to 18.5 on March 2026 . This represents a CAGR of -33.56% over 6 yearsThe P/E Ratio of Nidan Laboratories & Healthcare Ltd changed from 17.3 on March 2022 to 11.8 on March 2026 . This represents a CAGR of -7.37% over 5 years The Market Cap of Indraprastha Medical Corporation Ltd changed from ₹ 492.74 crore on March 2021 to ₹ 3407 crore on March 2026 . This represents a CAGR of 38.03% over 6 yearsThe Market Cap of Nidan Laboratories & Healthcare Ltd changed from ₹ 46.15 crore on March 2022 to ₹ 17.72 crore on March 2026 . This represents a CAGR of -17.42% over 5 years The revenue of Indraprastha Medical Corporation Ltd for the Sep '26 is ₹ 421.4 crore as compare to the Jun '26 revenue of ₹ 414.57 crore. This represent the growth of 1.65% The revenue of Nidan Laboratories & Healthcare Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Indraprastha Medical Corporation Ltd for the Sep '26 is ₹ 85.99 crore as compare to the Jun '26 ebitda of ₹ 88.23 crore. This represent the decline of -2.54% The ebitda of Nidan Laboratories & Healthcare Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Indraprastha Medical Corporation Ltd changed from ₹ 44.77 crore to ₹ 53.58 crore over 10 quarters. This represents a CAGR of 7.45% The net profit of Nidan Laboratories & Healthcare Ltd changed from ₹ 0 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of 0.0% The Dividend Payout of Indraprastha Medical Corporation Ltd changed from 39.1 % on March 2022 to 19.97 % on March 2026 . This represents a CAGR of -12.57% over 5 yearsThe Dividend Payout of Nidan Laboratories & Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Indraprastha Medical Corporation Ltd

Indraprastha Medical Corporation Limited was incorporated on 16th March, 1988.
The main business of the Company is to enhance the quality of life of patients by providing comprehensive, high-quality hospital services on a cost-effective basis.
The Company was formed as a joint venture between the Government of Delhi and the Apollo Hospitals Group to establish the Indraprastha Apollo Hospitals. The Hospital provides international standard medical care, offering a wide range of multi-specialty services.
Key specialties with strong growth and revenue potential include transplants, cardiology, oncology, neurology, and orthopaedics. The company came out with the public issue of 2,29,18,300 equity shares of Rs 10 each for cash at par aggregating Rs 22,91,83,000.
IMCL is setting up a multi-disciplinary super speciality teritary care referral hospital at New Delhi.

About Nidan Laboratories & Healthcare Ltd

Nidan Laboratories & Healthcare Limited was originally incorporated as Abhi Diagnostic Imagings Private Limited on December 05, 2000 with the Registrar of Companies, Maharashtra.
Subsequently, the name of the Company was changed from 'Abhi Diagnostic Imagings Private Limited' to 'Nidan Laboratories And Healthcare Private Limited' and fresh Certificate of Incorporation dated March 24, 2021 was issued by the Registrar of Companies.
The status of the Company was converted into a Public Limited Company and the name was changed to Nidan Laboratories & Healthcare Limited' on May 24, 2021.
At present, Company carry on the business of providing various Healthcare & Diagnostics Service Centres, such as X-Ray, Sonography, 2 D ECHO, PFT, CST, C.T. Scan, MRI, Blood Bank, Pathology Laboratories, Dialysis Unit, Intensive Care Unit, Burn & Poisoning Centre and Poly Clinic.

FAQs for the comparison of Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd

Which company has a larger market capitalization, Indraprastha Medical Corporation Ltd or Nidan Laboratories & Healthcare Ltd?

Market cap of Indraprastha Medical Corporation Ltd is 2,797 Cr while Market cap of Nidan Laboratories & Healthcare Ltd is 18 Cr

What are the key factors driving the stock performance of Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd?

The stock performance of Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd?

As of November 1, 2026, the Indraprastha Medical Corporation Ltd stock price is INR ₹305.15. On the other hand, Nidan Laboratories & Healthcare Ltd stock price is INR ₹13.0.

How do dividend payouts of Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd compare?

To compare the dividend payouts of Indraprastha Medical Corporation Ltd and Nidan Laboratories & Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.